Generate Biomedicines Raises $370 million Series C

Company profile · Healthcare & Life Sciences · Updated September 1, 2023

Generate Biomedicines has raised $370M in Series C funding led by Amgen, with participation from Amgen, Nvidia, ARCH Venture Partners. Advance AI-designed protein drugs into clinical trials. The funds will be used to Advance AI-designed protein drugs into clinical trials.

Series C$370 millionTotal tracked $740 millionSomerville, MA

What it does

Advance AI-designed protein drugs into clinical trials.

Traction

Biotechnology Market Accelerates Toward USD 6.34 Trillion by 2035 as AI, Gene Editing, and Advanced Biologics Reshape Global Healthcare The company is using its latest financing to scale, with the Series C round serving as the clearest current traction signal in the source bundle.

Trend impact

Advance AI-designed protein drugs into clinical trials. As adoption in Healthcare & Life Sciences expands, focused products from Generate Biomedicines can pressure incumbents or broader platforms that do not address the same problem directly.

Funding history

September 1, 2023 · Series C · $370 million · Amgen
December 1, 2021 · Series B · $370 million · Flagship

Products & services

Novel Therapeutic Modalities Target the Undruggable - Genetic capability
Engineering and Biotechnology News. Novel Therapeutic Modalities Target capability
Undruggable - Genetic Engineering and Biotechnology News capability
Genetic Engineering and Biotechnology News Biotechnology Market capability
Accelerates Toward USD 6.34 Trillion by 2035 as AI, Gene Editing, and capability

Open Generate Biomedicines in the interactive Capvizr dashboard →